New drug duo aims to stop liver Cancer's return after surgery
NCT ID NCT07324824
Summary
This study is testing whether giving two drugs—sintilimab and bevacizumab—before surgery can help people with liver cancer that has grown beyond certain size limits. The goal is to shrink tumors and, most importantly, lower the high chance of the cancer coming back after the tumor is surgically removed. Researchers will track patients for one year after surgery to see if the treatment helps keep them cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.